Last reviewed · How we verify
isatuximab SAR650984 IV
isatuximab SAR650984 IV is a Small molecule drug developed by Sanofi. It is currently in Phase 1 development. Also known as: Sarclisa.
At a glance
| Generic name | isatuximab SAR650984 IV |
|---|---|
| Also known as | Sarclisa |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Neutropenia
- Fatigue
- Constipation
- Diarrhoea
- Upper Respiratory Tract Infection
- Asthenia
- Nausea
- Back Pain
- Cough
- Pyrexia
- Headache
- Insomnia
Key clinical trials
- Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE2)
- Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE1)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis (PHASE1)
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency (PHASE2)
- Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE2)
- Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- isatuximab SAR650984 IV CI brief — competitive landscape report
- isatuximab SAR650984 IV updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about isatuximab SAR650984 IV
What is isatuximab SAR650984 IV?
isatuximab SAR650984 IV is a Small molecule drug developed by Sanofi.
Who makes isatuximab SAR650984 IV?
isatuximab SAR650984 IV is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
Is isatuximab SAR650984 IV also known as anything else?
isatuximab SAR650984 IV is also known as Sarclisa.
What development phase is isatuximab SAR650984 IV in?
isatuximab SAR650984 IV is in Phase 1.
What are the side effects of isatuximab SAR650984 IV?
Common side effects of isatuximab SAR650984 IV include Neutropenia, Fatigue, Constipation, Diarrhoea, Upper Respiratory Tract Infection, Asthenia.
Related
- Manufacturer: Sanofi — full pipeline
- Also known as: Sarclisa
- Compare: isatuximab SAR650984 IV vs similar drugs
- Pricing: isatuximab SAR650984 IV cost, discount & access